Home Cart Sign in  
Chemical Structure| 1232030-35-1 Chemical Structure| 1232030-35-1

Structure of FRAX486
CAS No.: 1232030-35-1

Chemical Structure| 1232030-35-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FRAX486 is a selective inhibitor of group I PAKs with IC50s of 8.25/39.5, /55.3 nM for PAK1/PAK2/PAK3 respectivelt and less potent for PAK4 (IC50=779 nM).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of FRAX486

CAS No. :1232030-35-1
Formula : C25H23Cl2FN6O
M.W : 513.39
SMILES Code : O=C1C(C2=CC=C(Cl)C=C2Cl)=CC3=CN=C(NC4=CC=C(N5CCNCC5)C(F)=C4)N=C3N1CC
MDL No. :MFCD26793866
InChI Key :DHKFOIHIUYFSOF-UHFFFAOYSA-N
Pubchem ID :68060125

Safety of FRAX486

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of FRAX486

cytoskeleton

Isoform Comparison

Biological Activity

Target
  • PAK

    PAK4, IC50:39 nM

    PAK1, IC50:14 nM

  • PAK1

    PAK1, IC50:14 nM

  • PAK3

    PAK3, IC50:39 nM

  • PAK2

    PAK2, IC50:33 nM

  • PAK4

    PAK4, IC50:575 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MV4-11 cells 1 µM 72 h FRAX-486 blocked proliferation and induced apoptosis in MV4-11 cells PMC11907924
P31/Fuj cells 10 µM 72 h FRAX-486 blocked proliferation and induced apoptosis in P31/Fuj cells PMC11907924
E0771 2 μM 24 h FRAX486 significantly inhibited migration and invasion of TNBC cells by blocking autophagic degradation of E-cadherin. PMC10844298
MDA-MB-231 2 μM 24 h FRAX486 significantly inhibited migration and invasion of TNBC cells by blocking autophagic degradation of E-cadherin. PMC10844298
Fibroblasts 50 nM 1 h To investigate the effect of FRAX486 on reversing the cellular phenotype caused by PAK1 mutations, results showed FRAX486 completely reversed the cellular phenotype PMC6174322
Primary hippocampal neurons 100 nM 48 h To evaluate the rescue effect of FRAX486 on CDKL5 deficiency-related neuronal maturation and synaptic defects. Results showed that FRAX486 completely rescued the abnormal neuronal maturation and the number of PSD95-positive puncta in Cdkl5-KO mouse neurons. PMC9532911
Trichophyton rubrum mycelia 3.1 µM 10 days To evaluate the inhibitory effect of FRAX486 on mycelial growth, results showed that FRAX486 significantly inhibited mycelial growth PMC10714743
Trichophyton rubrum spores 50 µM 21 h To evaluate the inhibitory effect of FRAX486 on spore germination, results showed that FRAX486 significantly inhibited spore germination PMC10714743

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Syrian hamsters SARS-CoV-2 infection model Oral 30 mg/kg Once daily for a total of four doses To evaluate the in vivo anti-SARS-CoV-2 activity of FRAX-486 PMC10560660
Mice Fmr1 KO mice Subcutaneous injection 20 mg/kg Single dose or daily for 5 days FRAX486 reversed the increased dendritic spine density, seizures, hyperactivity, and repetitive behaviors in Fmr1 KO mice. PMC3619302
Balb/c nude mice TNBC lung metastasis model Gavage 20 mg/kg 5 days per week for 7 weeks FRAX486 significantly reduced the number of lung metastatic nodules of TNBC cells, inhibiting autophagy-dependent metastasis. PMC10844298
NSG mice FLT3D835H PDX-ALL model Subcutaneous injection of FRAX486 and oral midostaurin 20 mg/kg Daily administration for 2-3 weeks Combined treatment significantly prolonged leukemia progression-free survival PMC6177654
NOD/SCID mice Subcutaneous xenograft model of MIA PaCa-2 cells Oral gavage 70 mg/kg Once daily for 14 days The combination of sotorasib with FRAX597 led to noticeable tumour regression. PMC9814377
Mice Female mouse model of CDKL5 deficiency disorder Subcutaneous injection 20 mg/kg Once daily for 5 consecutive days To assess the therapeutic effects of FRAX486 on behavioral abnormalities and metabolic defects in Cdkl5-Het mice. Results showed that FRAX486 improved general health status, hyperactive behavior, and fear learning deficits, and restored the levels of reactive oxidizing species in the blood and fasting-induced hypoglycemia. PMC9532911
Silkworm Silkworm infection model Injection 0.5 mM Single injection, survival monitored To evaluate the therapeutic effect of FRAX486 in the silkworm infection model, results showed that FRAX486 significantly improved survival rates PMC10714743

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.19mL

9.74mL

1.95mL

0.97mL

19.48mL

3.90mL

1.95mL

References

 

Historical Records

Categories